王茜朱旭友張灝楊孫和國(guó)李佳高青云易祥華
皮膚淋巴上皮瘤樣癌1例及文獻(xiàn)復(fù)習(xí)
王茜1,2,朱旭友3,張灝楊3,孫和國(guó)3,李佳1,2,高青云4,易祥華2,3
1. 上海市金山區(qū)亭林醫(yī)院病理科,上海 201505;2.上海市同濟(jì)醫(yī)院醫(yī)療集團(tuán)亭林醫(yī)院病理科,上海 201505;3.同濟(jì)大學(xué)附屬同濟(jì)醫(yī)院病理科,上海 200065;4.同濟(jì)大學(xué)附屬同濟(jì)醫(yī)院皮膚科,上海 200065
探討皮膚淋巴上皮瘤樣癌(LECS)的臨床和病理特征,提高臨床診斷和治療水平。對(duì)1例LECS患者的臨床表現(xiàn)、手術(shù)標(biāo)本大體病理形態(tài)、組織學(xué)表現(xiàn)和免疫組化表型進(jìn)行分析,并結(jié)合文獻(xiàn)復(fù)習(xí)?;颊邽槔夏昴行?,左面頰1.3 cm大小暗紅色質(zhì)硬結(jié)節(jié)狀皮損,切面實(shí)性,無(wú)明顯包膜。免疫組化顯示腫瘤細(xì)胞P-CK、CK5/6、EMA(+),S100和CDlα(部分+),Ki-67(+40%),PD-L1(+50%),P40、Melan-A、CEA(-);瘤細(xì)胞周圍增生的淋巴細(xì)胞LCA彌漫(+),癌巢內(nèi)及周邊淋巴細(xì)胞以CD3陽(yáng)性的T淋巴細(xì)胞為主。瘤細(xì)胞EBER原位雜交陰性反應(yīng)。面部皮膚淋巴上皮瘤樣癌極為罕見,病理形態(tài)和免疫組化表型與其他部位者相似,EBER檢查有鑒別診斷價(jià)值。腫瘤治療首選局部完整切除,預(yù)后相對(duì)較好。
淋巴上皮瘤樣癌;皮膚;免疫組化;診斷
皮膚淋巴上皮瘤樣癌(lymphoepithelioma-like carcinoma of the skin, LECS)是源于上皮的惡性腫瘤,伴有不同程度的淋巴細(xì)胞和漿細(xì)胞浸潤(rùn),尤其是發(fā)生在面頰部皮膚是極為罕見的皮膚惡性腫瘤?,F(xiàn)報(bào)道1例62歲男性患者,面頰部腫物近2月來(lái)逐漸增大,手術(shù)切除,既往無(wú)腫瘤史。結(jié)合國(guó)內(nèi)外文獻(xiàn),就皮膚淋巴上皮瘤樣癌的臨床和病理學(xué)特征及預(yù)后進(jìn)行探討,以提高對(duì)該病的認(rèn)識(shí)及診斷水平。
患者男性,62歲,發(fā)現(xiàn)左面頰腫物1年余,腫物紅豆大小,自行擠壓似有粉刺樣物排出,之后腫物周圍有僵硬感,1年多內(nèi)逐漸長(zhǎng)大,無(wú)明顯自覺癥狀,2個(gè)月前,腫物表面發(fā)紅,再次自行擠壓,無(wú)明顯改變,病程中無(wú)癢痛感?;颊邽檫M(jìn)一步診治,于2020年3月24日來(lái)同濟(jì)大學(xué)附屬同濟(jì)醫(yī)院門診就診。臨床檢查:左面頰暗紅色質(zhì)硬結(jié)節(jié)狀皮損,腫物最大徑約1.2 cm,表面光滑(圖1),無(wú)明顯壓痛及癢感。既往體健,身體其他部位無(wú)腫瘤史,無(wú)手術(shù)禁忌,在局麻下將腫物完整切除。
手術(shù)標(biāo)本經(jīng)4%中性甲醛溶液固定,常規(guī)石蠟包埋,切片厚4~5 μm,HE染色,光學(xué)顯微鏡下觀察。免疫組化采用EnVision二步法,DAB染色,蘇木精復(fù)染;一抗:廣譜細(xì)胞角蛋白(P-CK),細(xì)胞角蛋白5&6(CK5/6),細(xì)胞角蛋白7(CK7),上皮膜抗原(EMA),P53,Ki-67,S100,CDlα,PD-L1,P40,抗人黑色素(Melan-A),人癌胚抗原(CEA),細(xì)胞角蛋白20(CK20),bcl-2,CD30,CD3,CD20,淋巴細(xì)胞人白細(xì)胞共同抗原(LCA)試劑為DAKO公司產(chǎn)品。腫瘤細(xì)胞EB病毒編碼的小RNA(EBER)原位雜交檢查。
大體標(biāo)本經(jīng)甲醛固定后觀察,皮膚組織一塊,大小2 cm×1.5 cm×0.5 cm,皮膚中央有一灰白隆起,大小1.3 cm×1 cm×0.3 cm,切面見一灰白質(zhì)硬腫塊,大小1 cm×0.9 cm,邊界尚清,無(wú)明顯包膜。
低倍鏡下,腫物位于真皮深層,與表皮不相連,境界清楚(圖2)。中倍鏡下,腫瘤由聚集成團(tuán)的上皮樣細(xì)胞組成,細(xì)胞排列成分葉狀、巢狀或條索狀,部分巢團(tuán)有融合表現(xiàn)(圖3)。高倍鏡下,細(xì)胞胞質(zhì)輪廓不清,嗜伊紅染色,核空泡狀,可見明顯的核仁,核分裂象易見。癌巢內(nèi)及癌巢之間有明顯淋巴細(xì)胞和質(zhì)細(xì)胞浸潤(rùn)(圖4)。
腫瘤細(xì)胞P-CK(+),CK5/6(+)(圖5),CK7(+),EMA(+),P53(+),Ki-67(+40%),S100(部分+),CDlα(+5%),PD-L1(+約50%),P40(-),抗人黑色素(Melan-A)(-),人癌胚抗原(CEA)(-),細(xì)胞角蛋白20(CK20)(-),bcl-2(-),CD30(-),癌巢及周圍見增生的淋巴細(xì)胞LCA彌漫表達(dá),腫瘤細(xì)胞之間及癌巢周均可見CD3染色陽(yáng)性的T淋巴細(xì)胞(圖6),癌巢周圍可見CD20染色陽(yáng)性的B淋巴細(xì)胞,浸潤(rùn)的T淋巴細(xì)胞占明顯優(yōu)勢(shì)。原位雜交結(jié)果顯示EBER陰性。
(左面頰)皮膚淋巴上皮瘤樣癌(LECS),腫瘤切緣未見殘留腫瘤細(xì)胞。術(shù)后患者愈合良好,門診隨訪10個(gè)月無(wú)復(fù)發(fā)。
圖1 左面頰暗紅色質(zhì)硬結(jié)節(jié)狀皮損,表面光滑
Fig 1 The dark red hard nodular skin lesion on the left cheek with a smooth surface
圖2 低倍鏡下觀察,腫物位于真皮深層,與表皮不相連,邊界尚清,無(wú)明顯包膜(HE×12.5)
Fig 2 Under low power microscope, the tumor is located in the deep dermis and not connected with the epidermis, with clear boundary and no obvious capsule(HE×12.5)
圖3 中倍鏡下觀察,腫瘤由聚集成團(tuán)的上皮樣細(xì)胞組成,細(xì)胞排列成分葉狀、巢狀或條索狀,部分巢團(tuán)有融合表現(xiàn)(HE×200)
圖4 高倍鏡下觀察,細(xì)胞胞質(zhì)輪廓不清,嗜伊紅染色,核空泡狀,可見明顯的核仁,核分裂象易見,癌巢內(nèi)及癌巢之間有明顯淋巴細(xì)胞和漿細(xì)胞浸潤(rùn)(HE×400)
圖5 CK5/6免疫組化染色可見瘤細(xì)胞棕黃色陽(yáng)性表達(dá),呈條索狀排列(En Vision法)
圖6 腫瘤細(xì)胞之間及癌巢周均可見CD3染色陽(yáng)性的T淋巴細(xì)胞(En Vision法)
淋巴上皮瘤樣癌是起源于上皮的惡性腫瘤,最初在鼻咽部被報(bào)道,以后在胃、肺、胸腺和唾液腺等陸續(xù)被報(bào)道,偶見于喉、子宮頸和泌尿道[1-2]。LECS在1988年首次報(bào)道[3]。LECS極為少見,發(fā)生在面頰部皮膚更是極為罕見。該腫瘤在形態(tài)上與未分化鼻咽癌相似,一般為單發(fā)實(shí)性結(jié)節(jié),好發(fā)于老年人,無(wú)性別差異。頭頸部較為常見,偶見于肩、前壁和外陰等部位。目前缺乏大宗病例的隨訪資料報(bào)道,現(xiàn)有的資料顯示但該腫瘤預(yù)后相對(duì)較好。
LECS病理大體表現(xiàn)為境界比較清楚的結(jié)節(jié)狀皮損(腫塊),局部呈分葉狀,位于真皮和皮下,與表皮不相連。瘤細(xì)胞聚集成團(tuán),呈分葉狀、巢狀或條索狀排列。瘤細(xì)胞界限欠清,上皮樣,胞質(zhì)紅染呈嗜酸性,細(xì)胞核呈空泡狀;核仁明顯,單個(gè)或多個(gè),核分裂象易見,免疫組化顯示瘤細(xì)胞呈上皮標(biāo)記陽(yáng)性(細(xì)胞角蛋白和EMA染色陽(yáng)性),超微結(jié)構(gòu)分析顯示有橋粒和張力微絲。癌巢內(nèi)及癌巢周圍有彌漫的淋巴細(xì)胞、漿細(xì)胞浸潤(rùn),免疫組化顯示大多為B細(xì)胞,少數(shù)為T細(xì)胞表型。癌組織呈推進(jìn)性生長(zhǎng),周圍界限比較清楚,可以侵及周圍組織。腫瘤伴表達(dá),免疫組化可以顯示S100和CD1α陽(yáng)性的樹突狀細(xì)胞。如果CK5/6染色陽(yáng)性,提示瘤細(xì)胞向鱗狀細(xì)胞分化的趨向。有時(shí)瘤細(xì)胞可向附屬器分化,不具有特征性[4-5]。EB病毒在本例檢測(cè)結(jié)果陰性。文獻(xiàn)報(bào)道LECS中EB病毒均未檢出,而在未分化的鼻咽癌及其他部位如唾液腺、肺、胸腺和胃的淋巴上皮瘤樣癌均有被檢出;LECS可能與EB病毒感染無(wú)關(guān),與既往報(bào)道吻合,并且有一定的病理鑒別診斷價(jià)值[6-8]。
與已經(jīng)報(bào)道的皮膚外淋巴上皮瘤樣癌相比,本例具有以下特點(diǎn):(1)病變位于(左)面頰部,易受陽(yáng)光照射的部位。為暗紅色質(zhì)硬結(jié)節(jié)狀皮損,表面光滑。(2)腫物位于真皮深層,與表皮不相連,邊界尚清,無(wú)明顯包膜。瘤細(xì)胞周圍可見汗腺和皮脂腺,此形態(tài)不支持腫瘤為表皮來(lái)源。(3)腫瘤由聚集成團(tuán)的上皮樣細(xì)胞組成,細(xì)胞排列成分葉狀、巢狀或條索狀,部分巢團(tuán)有融合表現(xiàn)。CK5/6免疫組化陽(yáng)性,有鱗癌分化趨勢(shì);CK7陽(yáng)性,提示有腺上皮分化趨勢(shì)。如果浸潤(rùn)的淋巴細(xì)胞和漿細(xì)胞少的區(qū)域,此形態(tài)與低分化鱗癌很難區(qū)分。(4)腫瘤細(xì)胞之間及癌巢周均可見較多的淋巴細(xì)胞和漿細(xì)胞浸潤(rùn),CD20陽(yáng)性的B淋巴細(xì)胞主要在癌巢周分布,CD3陽(yáng)性的T淋巴細(xì)胞見于癌巢內(nèi)和癌巢之間。(5)EBER原位雜交結(jié)果顯示陰性,而肺、胸腺和胃的淋巴上皮瘤樣癌一般為陽(yáng)性,此點(diǎn)具有鑒別診斷意義。LECS主要為與以下疾病相鑒別[9-10]:(1)轉(zhuǎn)移性淋巴上皮瘤樣癌和轉(zhuǎn)移性未分化鼻咽癌:必須首先排除轉(zhuǎn)移性癌后才能考慮皮膚原發(fā)癌。鑒別點(diǎn):①是否有原發(fā)癌的病史,臨床檢查是否有原發(fā)腫瘤病灶;②轉(zhuǎn)移性癌一般多發(fā),常有淋巴結(jié)轉(zhuǎn)移;③轉(zhuǎn)移性淋巴上皮瘤樣癌幾乎所有病例EBER陽(yáng)性表達(dá),而LECS一般陰性反應(yīng)。(2)低分化鱗狀細(xì)胞癌和Merkel細(xì)胞癌:低分化鱗狀細(xì)胞癌伴有明顯的淋巴細(xì)胞浸潤(rùn)時(shí)與LECS鑒別困難;前者的免疫組化P40、P63染色陽(yáng)性,而后者一般為陰性有助于鑒別。Merkel細(xì)胞癌對(duì)CK20和神經(jīng)內(nèi)分泌標(biāo)記物呈陽(yáng)性反應(yīng)有助于鑒別診斷。(3)黑色素瘤和淋巴瘤:黑色素瘤瘤細(xì)胞免疫組化顯示S-100,Melan-A等陽(yáng)性表達(dá);淋巴瘤可通過(guò)淋巴樣標(biāo)記物進(jìn)行鑒別。(4)皮膚淋巴腺瘤:皮膚淋巴腺瘤以上皮細(xì)胞增生和淋巴細(xì)胞浸潤(rùn)為特點(diǎn),應(yīng)該與LECS進(jìn)行鑒別,前者表現(xiàn)為不規(guī)則的上皮細(xì)胞小葉和小梁陷于致密的纖維間質(zhì)中,腫瘤邊界清楚,無(wú)細(xì)胞異型性和病理核分裂象;腫瘤小葉邊緣為一層或多層呈珊欄狀排列的基底樣小細(xì)胞,免疫組化bcl-2陽(yáng)性表達(dá),這些與LECS不盡相同。(5)皮膚基底細(xì)胞癌:面部是皮膚基底細(xì)胞癌的好發(fā)部位,在病理形態(tài)學(xué)上應(yīng)該與LECS鑒別。前者的生長(zhǎng)方式分為非侵襲性及侵襲性兩種,主要表現(xiàn)為瘤細(xì)胞與表皮基底細(xì)胞相連;腫瘤周邊細(xì)胞呈柵欄狀排列;腫瘤內(nèi)黏液可形成較大的湖狀或囊腔;間質(zhì)為特征性的炎性黏液樣,其中可以具有比例不一的黏液、淋巴細(xì)胞、大量成纖維母細(xì)胞、膠原等成分;基底細(xì)胞癌的結(jié)節(jié)與周圍間質(zhì)之間可形成特征性的裂隙;癌巢內(nèi)和癌巢間淋巴細(xì)胞和漿細(xì)胞浸潤(rùn)較少;可表達(dá)一組類似毛囊干細(xì)胞(follicular germinative cells)表型的細(xì)胞角蛋白,如CK5/6、CK14,不表達(dá)CK20,可表達(dá)CK7, Ber-EP4一般強(qiáng)陽(yáng)性,p63為細(xì)胞核彌漫陽(yáng)性。以上不難與LECS鑒別。(6)肉芽腫性病變:肉芽腫性病變一般為感染或者非感染因素引起,所形成的肉芽腫結(jié)節(jié)與LECS的上皮樣的腫瘤細(xì)胞有時(shí)難以區(qū)分,需要鑒別。前者上皮樣細(xì)胞無(wú)異型性,無(wú)病理性核分裂象,為組織細(xì)胞源性,免疫組化顯示CD68等組織細(xì)胞標(biāo)記物陽(yáng)性反應(yīng),P-CK等上皮細(xì)胞標(biāo)記物陰性,后者瘤細(xì)胞為上皮源性,CK表達(dá),有助于鑒別。
面頰部LECS是十分罕見的惡性腫瘤,治療應(yīng)盡可能外科手術(shù)將腫瘤完全切除,預(yù)后較好。如果不能完整外科手術(shù)切除的患者可以考慮術(shù)后輔助放療[10]。目前缺乏大宗病例的隨訪資料報(bào)道,LECS的確切預(yù)后還需要積累更多的病例資料。
[1] Welch PQ, Williams SB, Foss RD, et al. Lymphoepithelioma-like carcinoma of head and neck skin:A systematic analysis of 11 cases and review of literature [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 111(1): 78-86.
[2] Labgaa I, Stueck A, Ward S C. Lymphoepithelioma-like carcinoma in liver [J]. Am J Pathol, 2017,187(7):1438-1444.
[3] Swanson SA, Cooper PH, Mills SE, et a1. Lymphoepithelioma-like carcinoma of the skin[J]. Mod Pathol, 1988,1(5):359-365.
[4] Shek T W, Leung E Y, Luk L S, et al. Lymphoepithelioma-like carcinoma of the skin[J]. Am J Dermatopathol,1996, 18 (6):637-644.
[5] Hinz T, Wiechert A. Lymphoepithelioma-like carcinoma of the skin mimicking a basal cell carcinoma[J]. Eur J Dermatol, 2009,60(2):179-180.
[6] Arsenovic N. Lymphoepithelioma-like carcinoma of the skin:New case of an exceedingly rare primary skin tumor[J].Dermatol Online J, 2008,14(8):12.
[7] Hur YH, Kim H H, Koh YS, et al. Lymphoepithelioma-like cholangiocarcinoma not associated with Epstein-Barr virus[J]. ANZ J Surg, 2011,81(9):652-653.
[8] Lee W. Intrahepatic lymphoepithelioma-like cholangiocarcinoma not associated with epstein-barr virus: A case report[J]. Case Rep Oncol, 2011,4(1):68-73.
[9] Mucha-Ma?ecka A, Urbanek K, Ambicka A, et al. Radiotherapy in lymphoepithelioma-like carcinoma of the skin: Review of the literature and report of arecurrent and metastatic case[J]. Strahlenther Onkol, 2019,195(11):1028-1032.
[10] Oliveira CC, Nóbrega VC, Marques MEA. Lymphoe-pithelioma-like carcinoma of the skin[J]. An Bras Dermatol, 2018,93(2):256-258.
Lymphoepithelioma-like carcinoma of the skin: A case report and literature review
1,2,3,3,3,1,2,4,2,3
1,,,201505,;2,,,201505,;3,,200065,;4,,200065,
To investigate the clinical and pathological features of lymphoepithelioma-like carcinoma of the skin (LECS) and improve clinical diagnosis and treatment of the disease.The clinical manifestations, gross pathological morphology, histological features, and immunohistochemical phenotype of a patient with LECS were analyzed, and the related literature was reviewed.The patient was an elderly male with a 1.3 cm dark red hard nodular lesion on the left cheek. The nodule was solid and without obvious capsule. Immunohistochemical results showed that the tumor cells were stained positive for P-CK, CK5/6, EMA, S100 and CD1α (partial positive expression), Ki-67(40%), and PD-L1(50%), and negative for P40, Melan-A, and CEA. The proliferative lymphocytes around the tumor cells were diffuse positive for LCA, and the lymphocytes in and around the cancer nest were mainly CD3 positive T lymphocytes. EBERhybridization of tumor cells was negative.LECS on the check is very rare, and its pathological morphology and immunohistochemical phenotype are similar to those in other sites. EBER examination is valuable in differential diagnosis. Local complete resection is the first choice for the treatment of the tumor, and the prognosis is relatively good.
Lymphoepithelioma-like carcinoma; Skin; Immunohistochemistry; Diagnosis
R739.5
A
2095-378X(2022)01-0051-05
10.3969/j.issn.2095-378X.2022.01.013
國(guó)家自然科學(xué)基金(82170082);上海市科學(xué)技術(shù)委員會(huì)醫(yī)學(xué)重點(diǎn)科技攻關(guān)專項(xiàng)基金(09411951600);上海市自然科學(xué)基金(19ZR1448500);上海市衛(wèi)生局醫(yī)學(xué)重點(diǎn)專項(xiàng)基金(20134034);上海市科學(xué)技術(shù)委員會(huì)醫(yī)學(xué)引導(dǎo)類項(xiàng)目基金(19411964700);上海市金山區(qū)衛(wèi)生健康委員會(huì)面上項(xiàng)目(JSKJ-KTMS-2019-22)
王茜(1981—),女,大學(xué)本科,主治醫(yī)師,從事病理學(xué)診斷工作
易祥華,電子信箱:yixhxf@163.com
(2021-01-27)